Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.49 |
| ▸ | MMP13 | P45452 | 4/20 | 0.49 |
| ▸ | MMP2 | P08253 | 9/20 | 0.45 |
| ▸ | MMP3 | P08254 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | FCER2 | P06734 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488362 | 1.00 | MMP1 (0.49) | MMP1MMP13MMP2MMP3CTSL | |
| SCHEMBL13333366 | 0.87 | CACNA1B (0.43) | CTSLCTSBCTSSCTSK | |
| SCHEMBL7045270 | 0.87 | CACNA1B (0.43) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5488359 | 0.82 | LTA4H (0.47) | MMP1MMP13MMP2MMP3CTSS | |
| SCHEMBL5488356 | 0.82 | LTA4H (0.47) | MMP1MMP13MMP2MMP3CTSS | |
| SCHEMBL14492864 | 0.80 | MMP1 (0.47) | MMP1MMP13MMP2MMP3CTSL | |
| SCHEMBL7045267 | 0.80 | SLC15A1 (0.45) | CTSLCTSBCTSSCTSK | |
| SCHEMBL7045269 | 0.80 | SLC15A1 (0.45) | CTSLCTSBCTSSCTSK | |
| SCHEMBL7430436 | 0.78 | CTSS (0.50) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5488738 | 0.78 | MMP1 (0.43) | MMP1MMP13MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129310-A1 | Antibacterial agents | VERNALIS (OXFORD) LTD. (GB) | 2007-06-07 | — | — | US | disclosed |
| US-20070129310-A1 | Antibacterial agents | VERNALIS (OXFORD) LTD. (GB) | 2007-06-07 | — | — | US | disclosed |
| US-20070129310-A1 | Antibacterial agents | VERNALIS (OXFORD) LTD. (GB) | 2007-06-07 | — | — | US | disclosed |
| EP-1554261-A1 | ANTIBACTERIAL AGENTS | Vernalis (Oxford) Limited (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004033441-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129310-A1 | Antibacterial agents | ARG1, SCO2, SPOUT1 | MMP1 3562/4885MMP13 3787/4885MMP2 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.